Has Pamela Walls, APRN received payments from drug or device companies?

Yes. Drug and device makers reported $823 in general payments to Pamela Walls, APRN across 43 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pamela Walls, APRN did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pamela Walls, APRN come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pamela Walls, APRN

Psychiatric/Mental Health · Minot, NDNPI 1962573394

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $248, 4.8 times the $52 reported in 2021.

$823in general payments, 2019–2025

Across 43 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
Otsuka America Pharmaceutical, Inc.$122
Teva Pharmaceuticals USA, Inc.$91
Neurocrine Biosciences, Inc.$87
Takeda Pharmaceuticals U.S.A., Inc.$69
Axsome Therapeutics, Inc.$64
plus $241 from 7 others

What the payments were for

Food & beverage$77794%
Education$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	6	$149
Otsuka America Pharmaceutical, Inc.	6	$122
Teva Pharmaceuticals USA, Inc.	5	$91
Neurocrine Biosciences, Inc.	5	$87
Takeda Pharmaceuticals U.S.A., Inc.	4	$69
Axsome Therapeutics, Inc.	3	$64
Alkermes, Inc.	3	$59
E.r. Squibb & Sons, L.L.C.	3	$51
Collegium Pharmaceutical, Inc.	3	$50
Lundbeck LLC	2	$28
Merck	1	$20
Tempus AI, Inc	1	$19
Johnson & Johnson	1	$13

How this compares

$823 in reported general payments places this provider in the 75th percentile of 92 psychiatric/mental health providers in North Dakota.

See all psychiatric/mental health providers in North Dakota →

Medicare billing

Part B allowed, 2024

$30,609

Medicare patients

Services billed

352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AustedoDeutetrabenazine	19	$66,359
Abilify MaintenaAripiprazole	24	$59,849
Invega SustennaPaliperidone Palmitate	14	$45,032
VraylarCariprazine Hcl	12	$15,887
Lurasidone Hcl	19	$8,731
FetzimaLevomilnacipran Hcl	12	$6,055
Atomoxetine Hcl	39	$3,653
Clozapine	26	$3,306
Hydroxyzine Hcl	81	$2,649
Divalproex Sodium ErDivalproex Sodium	35	$2,314
Olanzapine	92	$1,908
Duloxetine Hcl	118	$1,705
Guanfacine Hcl ErGuanfacine Hcl	14	$1,640
Trazodone Hcl	105	$1,576
Aripiprazole	52	$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo	$91	$66,35919 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena	$122	$59,84924 claims
Johnson & JohnsonInvega Sustenna	$13	$45,03214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 psychiatric/mental health providers in North Dakota.

Other psychiatric/mental health in Minot

Roxann BrownMinot$3K
Tonya AndersonMinot$3K
Jennifer WoiwodeMinot$2K
Bobbie BusethMinot$2K
Tammy UlebergMinot$2K
Kiley AndreasMinot$2K
Stacy FlatenMinot$987
Melissa ScheppMinot$797
Alicja CebulakMinot$661
Amanda DaggettMinot$545

See the full list for North Dakota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →